deltatrials
Unknown PHASE3 INTERVENTIONAL 2-arm NCT00454389

A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration (CABERNET)

A Randomized, Prospective, Active Controlled, Study of the Epi-Rad90™ Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration

Sponsor: NeoVista

Conditions Macular Degeneration
Interventions Epi-Rad90™ Ophthalmic System ranibizumab
Updated 7 times since 2017 Last updated: Jul 26, 2011 Started: Apr 30, 2007 Primary completion: Sep 30, 2011 Completion: Aug 31, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Macular Degeneration and is currently ongoing. NeoVista leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotUnknown Status~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 12 months · monthly snapshotUnknown

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Unknown Status PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Unknown Status PHASE3

    First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NeoVista
Data source: NeoVista

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augusta, United States , Austin, United States , Barcelona, Spain , Belfast, Ireland , Beverly Hills, United States , Boston, United States , Campbell, United States , Charlotte, United States , Cincinnati, United States , Fort Lauderdale, United States and 20 more locations